Jan A. Burger

The University of Texas MD Anderson Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine(2013)10.1056/nejmoa1215637

N/A

18.9DataRank · unranked

2265 citations

Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +16 more

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2856

N/A

4.5DataRank · unranked

184 citations

Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Nature Genetics(2022)10.1038/s41588-022-01140-w

N/A

0.753DataRank · unranked

150 citations

Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson +34 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0.312DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report

Leukemia Research Reports(2023)10.1016/j.lrr.2023.100377

N/A

0DataRank · unranked

3 citations

William F. Glass, Jamie S. Lin, Jan A. Burger, Anna-Ève Turcotte

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

Cancer Cell(2021)10.1016/j.ccell.2021.02.003

N/A

0DataRank · unranked

60 citations

Shanye Yin, Elisa Ten Hacken, Tomasz Sewastianik, Mohamed Uduman, Alba Font‐Tello +24 more

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application

Haematologica(2023)10.3324/haematol.2023.283178

N/A

0DataRank · unranked

1 citations

Terri Rasmussen, Lorena Fontán, Min Xia, Ari Melnick, Adrian Wiestner +7 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood(2023)10.1182/blood-2023-190712

N/A

0DataRank · unranked

1 citations

David Harris, Uri Rozovski, Ping Li, Zhiming Liu, Taghi Manshouri +15 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children’s Oncology Group

International Journal of Molecular Sciences(2023)10.3390/ijms24065460

N/A

0DataRank · unranked

2 citations

Ti’ara L. Griffen, Brandon D. Brown, Terzah M. Horton, Jan A. Burger, William G. Wierda +4 more

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

Leukemia(2021)10.1038/s41375-021-01181-w

N/A

0DataRank · unranked

29 citations

Christopher P. Mill, Dimuthu Perera, Christine Birdwell, Qing Deng, Haopeng Yang +13 more

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood(2021)10.1182/blood.2021012315

N/A

0DataRank · unranked

24 citations

Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson +4 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more